MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Merck & Co., Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$143.63−2.32 (-1.59%)
Close on Oct 19, 2026
- Market cap
- $354.77B
- P/E (TTM)
- 114.9
- Dividend yield
- 2.28%
Merck & Co., Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical | $58.14B | $57.40B | $53.58B | $52.01B | $42.75B | $36.61B | $34.10B | $37.69B | $35.39B | $35.15B | 89.4% | +1.3% |
| Animal Health | $6.35B | $5.88B | $5.63B | $5.55B | $5.57B | $4.70B | $4.39B | $4.21B | $3.88B | $3.48B | 9.8% | +8.1% |
| Other segments | – | – | – | $0 | $0 | $23.00M | $175.00M | $250.00M | $397.00M | $385.00M | – | – |
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $36.51B | $32.28B | $28.48B | $27.21B | $22.43B | $19.59B | $18.42B | $18.23B | $17.42B | $18.45B | 56.2% | +13.1% |
| Non-US | $28.13B | $31.13B | $30.87B | – | – | – | – | – | – | – | 43.3% | -9.6% |
| Europe, Middle East and Africa | $14.58B | $14.04B | $13.25B | $14.49B | $13.34B | $11.55B | $10.50B | $12.21B | $11.48B | $10.95B | 22.4% | +3.8% |
| Latin America | $3.41B | $3.46B | $3.09B | $2.58B | $2.21B | $1.89B | $2.02B | $2.42B | $2.34B | $2.16B | 5.2% | -1.4% |
| Asia Pacific (other than China and Japan) | $2.98B | $3.06B | $3.23B | $3.61B | $2.41B | $2.11B | $2.13B | $2.91B | $2.75B | $2.48B | 4.6% | -2.5% |
| Other | $2.88B | $2.56B | $2.10B | $2.57B | $1.22B | $1.03B | $1.28B | $1.02B | $1.42B | $1.46B | 4.4% | +12.5% |
| Japan | $2.71B | $3.28B | $3.16B | $3.63B | $2.73B | $2.60B | $2.61B | $3.21B | $3.12B | $2.85B | 4.2% | -17.3% |
| China | $1.94B | $5.49B | $6.80B | $5.19B | $4.38B | $2.75B | $2.18B | $2.18B | $1.59B | $1.44B | 3.0% | -64.7% |
| Intl | – | $31.89B | $31.64B | $32.08B | $26.28B | $21.93B | $20.70B | $23.92B | $22.32B | $20.57B | – | – |
From the segment and revenue-disaggregation notes of Merck's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.